Eagle Pharmaceuticals, Inc. - Common Stock (NQ:EGRX)

2.140 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist

Price and Volume

Volume	0
Open	2.140
Bid (Size)	2.270 (191)
Ask (Size)	2.330 (37)
Prev. Close	2.140
Today's Range	2.140 - 2.140
52wk Range	N/A - N/A
Shares Outstanding	12,698,566
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 02, 2024

Via Benzinga

Crude Oil Edges Higher; ConAgra Posts Downbeat Earnings ↗

October 02, 2024

Via Benzinga

Performance

More News

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 02, 2024

Via Benzinga

Dow Gains 100 Points; Joby Aviation Shares Spike Higher ↗

October 02, 2024

Via Benzinga

US Stocks Edge Lower; Private Employment Beats Expectations ↗

October 02, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 22, 2024

Via Benzinga

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

February 08, 2024

From The Law Offices of Frank R. Cruz

Via Business Wire

EAGLE PHARMACEUTICALS 48 HOUR DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options

February 08, 2024

From Faruqi & Faruqi LLP

Via GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX

February 06, 2024

Via NewMediaWire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX

February 06, 2024

Via TheNewswire.com

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Pharmaceuticals, Golden Heaven, Inspire Medical, and Driven and Encourages Investors to Contact the Firm

February 04, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action – EGRX

February 04, 2024

From The Rosen Law Firm PA

Via GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX

February 02, 2024

Via NewMediaWire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX

February 02, 2024

Via TheNewswire.com

ROSEN, A LEADING LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action – EGRX

February 01, 2024

From The Rosen Law Firm PA

Via GlobeNewswire

EAGLE PHARMACEUTICALS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options

February 01, 2024

From Faruqi & Faruqi LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Microvast, Eagle Pharmaceuticals, Golden Heaven, and Inspire Medical and Encourages Investors to Contact the Firm

January 31, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX

January 29, 2024

Via NewMediaWire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX

January 29, 2024

Via TheNewswire.com

ROSEN, A TOP RANKED LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX

January 28, 2024

Via NewMediaWire

ROSEN, A TOP RANKED LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important February 9 Deadline in Securities Class Action - EGRX

January 28, 2024

Via TheNewswire.com

January 27, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

EAGLE PHARMACEUTICALS SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options

January 24, 2024

From Faruqi & Faruqi LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fisker, Microvast, Eagle Pharmaceuticals, and Golden Heaven and Encourages Investors to Contact the Firm

January 23, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Eagle Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EGRX

January 23, 2024

Via NewMediaWire

Frequently Asked Questions

Is Eagle Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Eagle Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Eagle Pharmaceuticals, Inc. - Common Stock trade on?

Eagle Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Eagle Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Eagle Pharmaceuticals, Inc. - Common Stock is EGRX on the Nasdaq Stock Market

What is the current price of Eagle Pharmaceuticals, Inc. - Common Stock?

The current price of Eagle Pharmaceuticals, Inc. - Common Stock is 2.140

When was Eagle Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Eagle Pharmaceuticals, Inc. - Common Stock was at 10/02/24 04:00 PM ET

What is the market capitalization of Eagle Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Eagle Pharmaceuticals, Inc. - Common Stock is 27.17M

How many shares of Eagle Pharmaceuticals, Inc. - Common Stock are outstanding?

Eagle Pharmaceuticals, Inc. - Common Stock has 27M shares outstanding.